Authors: Pivot, X Wadler, S Kelly, C Ruxer, R Tortochaux, J Stern, J Belpomme, D Humblet, Y Domenge, C Clendeninn, N Johnston, A Penning, C Schneider, M

Citation: X. Pivot et al., Result of two randomized trials comparing nolatrexed (Thymitaq (TM)) versus methotrexate in patients with recurrent head and neck cancer, ANN ONCOL, 12(11), 2001, pp. 1595-1599

Authors: Saag, MS Tebas, P Sension, M Conant, M Myers, R Chapman, SK Anderson, R Clendeninn, N

Citation: Ms. Saag et al., Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511), AIDS, 15(15), 2001, pp. 1971-1978

Authors: Mittler, J Essunger, P Yuen, GJ Clendeninn, N Markowitz, M Perelson, AS

Citation: J. Mittler et al., Short-term measures of relative efficacy predict longer-term reductions inhuman immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy, ANTIM AG CH, 45(5), 2001, pp. 1438-1443

Authors: Estlin, EJ Pinkerton, CR Lewis, IJ Lashford, L McDowell, H Morland, B Kohler, J Newell, DR Boddy, AV Taylor, GA Price, L Ablett, S Hobson, R Pitsiladis, M Brampton, M Clendeninn, N Johnston, A Pearson, ADJ

Citation: Ej. Estlin et al., A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation, BR J CANC, 84(1), 2001, pp. 11-18

Authors: Hughes, AN Rafi, I Griffin, MJ Calvert, AH Newell, DR Calvete, JA Johnston, A Clendeninn, N Boddy, AV

Citation: An. Hughes et al., Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days, CLIN CANC R, 5(1), 1999, pp. 111-118